Background and Objective: Adding belzutifan to adjuvant pembrolizumab improved disease-free survival (DFS) in LITESPARK-022, but its durability beyond the 1-year treatment is unknown. Methods: Following a registered plan, we reconstructed individual patient data from published Kaplan-Meier curves of ten phase 3 adjuvant renal cell carcinoma trials. Within each trial, we estimated restricted mean survival time differences ({Delta}RMST), hazard ratios (HRs) before and after planned treatment ended, and DFS differences.
Does the Disease-free Survival Benefit of Adding Belzutifan to Adjuvant Pembrolizumab Persist Beyond the Planned Treatment Period? A Reconstructed Individual Patient Data Analysis of Phase 3 Renal Cell Carcinoma Trials
calendar_today
October 16, 2026
person
Chang, H.-H., Chang, C.-K., Tang, T.-Y., Jhan, J.-H., Dong, S.-W., Juan, Y.-S., Geng, J.-H., Ou, H.-C., Lee, H.-Y., Li, C.-Y., Yeh, H.-C., Leong, M.-K., Liu, C.-H., Lee, Y.-C., Huang, S.-P.
domain
medrxiv